BusinessPhoto: NDTV BusinessSun Pharma Q2 Results: Mixed Brokerage Reviews, Citi and HSBC Maintain Buy
Sun Pharma reported a 36.2% year-on-year net profit decline to Rs 1,989 crore in Q2, with revenue rising 11.9% to Rs 16,199 crore and EBITDA up 4.8% to Rs 4,744 crore. Despite beating estimates, concerns remain over its US specialty business and R&D spending. Citi and HSBC maintained Buy ratings, while BofA downgraded to Underperform and cut price targets.
NDTV Business·




